The best use of chemotherapy in the adjuvant setting, The Breast, vol.12, issue.6, pp.522-528, 2003. ,
DOI : 10.1016/S0960-9776(03)00161-9
Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy, Journal of Clinical Oncology, vol.17, issue.2, pp.460-469, 1999. ,
DOI : 10.1200/JCO.1999.17.2.460
Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer, Oncology Reports, vol.14, pp.513-520, 2005. ,
DOI : 10.3892/or.14.2.513
Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update, Journal of Clinical Oncology, vol.24, issue.12, pp.1940-1949, 2006. ,
DOI : 10.1200/JCO.2005.02.6187
International Expert Panel on the Use of Primary (Preoperative) Systemic Treatment of Operable Breast Cancer: Review and Recommendations, Journal of Clinical Oncology, vol.21, issue.13, pp.2600-2608, 2003. ,
DOI : 10.1200/JCO.2003.01.136
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer, The Lancet, vol.362, issue.9381, pp.362-369, 2003. ,
DOI : 10.1016/S0140-6736(03)14023-8
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy, Clinical Cancer Research, vol.11, issue.16, pp.5678-5685, 2005. ,
DOI : 10.1158/1078-0432.CCR-04-2421
Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance, Breast Cancer Research and Treatment, vol.22, issue.3, pp.229-233, 2006. ,
DOI : 10.1007/s10549-005-9009-7
Intrinsic tumour suppression, Nature, vol.35, issue.7015, pp.307-315, 2004. ,
DOI : 10.1038/nature03098
Disruption of p53 in human cancer cells alters the responses to therapeutic agents, Journal of Clinical Investigation, vol.104, issue.3, pp.263-269, 1999. ,
DOI : 10.1172/JCI6863
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias, Blood, vol.85, pp.1580-1589, 1995. ,
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response, Blood, vol.104, issue.5, pp.1428-1434, 2004. ,
DOI : 10.1182/blood-2003-09-3236
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients, Nature Medicine, vol.19, issue.7, pp.811-814, 1996. ,
DOI : 10.1016/0959-8049(94)00213-O
From The Cover: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival, Proceedings of the National Academy of Sciences, vol.102, issue.38, pp.13550-13555, 2005. ,
DOI : 10.1073/pnas.0506230102
TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients, Clin Cancer Res, vol.6, pp.50-56, 2000. ,
The Clinical Value of Somatic TP53 Gene Mutations in 1,794 Patients with Breast Cancer, Clinical Cancer Research, vol.12, issue.4, pp.1157-1167, 2006. ,
DOI : 10.1158/1078-0432.CCR-05-1029
Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy, Annals of Oncology, vol.17, issue.10, pp.1504-1511, 2006. ,
DOI : 10.1093/annonc/mdl147
Prognostic significance ofp53 mutation in breast cancer: Frequent detection of non-missense mutations by yeast functional assay, International Journal of Cancer, vol.44, issue.6, pp.587-593, 1999. ,
DOI : 10.1002/(SICI)1097-0215(19991222)84:6<587::AID-IJC8>3.0.CO;2-8
High-dose epirubicin and cyclophosphamide every two weeks as first-line chemotherapy for relapsing metastatic breast cancer patients, Annals of Oncology, vol.10, issue.7, pp.795-801, 1999. ,
DOI : 10.1023/A:1008353904351
TNM: Classification of malignant tumours, 2002. ,
DOI : 10.1002/0471463752
pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology, vol.9, issue.5, pp.403-410, 1991. ,
DOI : 10.1016/0277-5379(88)90171-X
Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy, The Lancet, vol.360, issue.9336, pp.852-854, 2002. ,
DOI : 10.1016/S0140-6736(02)09969-5
A simple p53 functional assay for screening cell lines, blood, and tumors., Proceedings of the National Academy of Sciences, vol.92, issue.9, pp.3963-3967, 1995. ,
DOI : 10.1073/pnas.92.9.3963
Field cancerisation and polyclonal p53 mutation in the upper aero- digestive tract, Oncogene, vol.14, issue.2, pp.163-169, 1997. ,
DOI : 10.1038/sj.onc.1200812
Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome, The American Journal of Pathology, vol.161, issue.6, pp.1991-1996, 2002. ,
DOI : 10.1016/S0002-9440(10)64476-8
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma, Clinical Cancer Research, vol.10, issue.16, pp.5367-5374, 2004. ,
DOI : 10.1158/1078-0432.CCR-04-0220
p16INK4a protein expression is associated with poor survival of the breast cancer patients after CMF chemotherapy, Breast Cancer Research and Treatment, vol.16, issue.3, pp.205-212, 2001. ,
DOI : 10.1023/A:1013047413895
Overexpression of the p16 Cell Cycle Inhibitor in Breast Cancer is Associated with a More Malignant Phenotype, Breast Cancer Research and Treatment, vol.93, issue.1, pp.61-70, 2001. ,
DOI : 10.1023/A:1010623308275
Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation, British Journal of Cancer, vol.78, issue.12, pp.1661-1668, 1998. ,
DOI : 10.1038/bjc.1998.739
Breast cancer classification and prognosis based on gene expression profiles from a population-based study, Proceedings of the National Academy of Sciences, vol.100, issue.18, pp.10393-10398, 2003. ,
DOI : 10.1073/pnas.1732912100
Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF, Annals of Oncology, vol.16, issue.5, pp.743-748, 2005. ,
DOI : 10.1093/annonc/mdi150
Molecular portraits of human breast tumours, Nature, vol.406, issue.6797, pp.747-752, 2000. ,
DOI : 10.1038/35021093
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proceedings of the National Academy of Sciences, vol.98, issue.19, pp.10869-10874, 2001. ,
DOI : 10.1073/pnas.191367098
p53 and cancer therapy: a double-edged sword, Journal of Clinical Investigation, vol.104, issue.3, pp.223-225, 1999. ,
DOI : 10.1172/JCI7861
Factors determining cell killing by chemotherapeutic agents In Vivo???II., European Journal of Cancer (1965), vol.7, issue.1, pp.11-17, 1971. ,
DOI : 10.1016/0014-2964(71)90089-2
Immediate Gene Expression Changes After the First Course of Neoadjuvant Chemotherapy in Patients with Primary Breast Cancer Disease, Clinical Cancer Research, vol.10, issue.19, pp.6418-6431, 2004. ,
DOI : 10.1158/1078-0432.CCR-04-1031
Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents, Oncogene, vol.23, issue.39, pp.6548-6558, 2004. ,
DOI : 10.1038/sj.onc.1207873
???Amplified Breast Cancer: Scandinavian Breast Group Trial 9401, Journal of Clinical Oncology, vol.24, issue.16, pp.2428-2436, 2006. ,
DOI : 10.1200/JCO.2005.02.9264
Cancer biology: Can less be more for p53?, Nature, vol.2, issue.7108, pp.153-154, 2006. ,
DOI : 10.1038/443153a
Identification of human brain tumour initiating cells, Nature, vol.64, issue.7015, pp.396-401, 2004. ,
DOI : 10.1038/nature03128
Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death, Cancer Cell, vol.8, issue.1, pp.7-12, 2005. ,
DOI : 10.1016/j.ccr.2005.06.011
Tumour response to preoperative anthracycline-based chemotherapy in operable breast cancer: the predictive role of p53 expression, European Journal of Cancer, vol.42, issue.10, pp.1369-1379, 2006. ,
DOI : 10.1016/j.ejca.2006.01.054
Basal-like breast carcinomas: clinical outcome and response to chemotherapy, Journal of Clinical Pathology, vol.59, issue.7, pp.729-735, 2006. ,
DOI : 10.1136/jcp.2005.033043
Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741, Journal of Clinical Oncology, vol.21, issue.8, pp.1431-1439, 2003. ,
DOI : 10.1200/JCO.2003.09.081